Summaries of Product Characteristics (SPC) for Human medicinal products

The summaries of product characteristics (SPC) contain the information relevant to the use of the medicinal products and of importance to health care professionals. The SPCs are published in Finnish; the use of Finnish key words in the search fields is therefore recommended.

Some of the medicinal products contain a condition relevant to the prescribing of the product and not always found in the SPC. The conditions for prescribing and the products covered by this condition are found in the FimeaWeb search.

The SPCs processed as part of the EU centralised marketing authorisation procedure are published by the European Medicines Agency, EMA. Fimea's service contains links to the documents on medicinal products (EPAR PI) on the EMA website. Drugs belonging to the centralised authorisation procedure can be searched in Fimea's service by using an alphabetical list or by entering the product name or ATC code.

The material being published is not necessarily complete or up-to-date due to the technical quality of files submitted to the Finnish Medicines Agency Fimea or earlier to the National Agency for Medicines and the delays in delivery. For this reason, Fimea cannot guarantee that the document on the Internet fully complies with the summary of product characteristics and package leaflet officially approved by a desicion for a marketing authorisation. Only the hard copies of the SPCs and the PLs, which are in accordance with the marketing authorisation, are conclusive.

Search with the first character of the name of the medicinal product: n

Summaries of Product Characteristics 1 - 30 of 206
1  2  3  4  5  6  7  |  Next 30   >
Package leaflet	Status for supply	Name of the medicinal product
		European Medicines Agency's website: Naglazyme - EMA: EPAR PI Finnish Swedish
PL	Resepti	Naldix 50 mg tabletti, kalvopäällysteinen SPC 2023-02-28
PL	Resepti	Nalgesin 220 mg tabletti, kalvopäällysteinen SPC 2023-04-13
PL	Resepti	Naloxon B. Braun 0.4 mg-ml injektio-infuusioneste, liuos SPC 2019-09-26
PL	Resepti	Naloxone Accord 0,4 mg-ml injektio-infuusioneste, liuos, esitäytetty ruisku SPC 2023-02-01.docx
PL	Resepti	Naltrexon Accord 50 mg tabletti, kalvopäällysteinen SPC 2022-04-25
PL	Resepti	Naltrexon Vitaflo 50 mg tabletti, kalvopäällysteinen SPC 2022-03-18
PL	Resepti	Naltrexone Poa Pharma 50 mg tabletti, kalvopäällysteinen SPC 2023-02-28
		European Medicines Agency's website: Namuscla - EMA: EPAR PI Finnish Swedish
PL	Resepti	Nanogam 100 mg-ml infuusioneste, liuos SPC 2022-11-17
PL	Resepti	Nanogam 50 mg-ml infuusioneste, liuos SPC 2021-12-17
PL	Resepti	Naprometin 500 mg tabletti SPC 2023-03-23
PL	Resepti	Napromex 500 mg tabletti, kalvopäällysteinen SPC 2022-10-26
PL	Resepti	Naproxen Krka 550 mg tabletti, kalvopäällysteinen SPC 2022-09-22
PL	Resepti	Naproxen Mylan 500 mg tabletti SPC 2022-09-20
PL	Resepti	Naproxen Orion 250 mg, 500 mg tabletti SPC 2022-09-14
PL	Resepti	Naramig 2.5 mg tabletti, kalvopäällysteinen SPC 2023-09-22
PL	Resepti	Naratriptan Orifarm 2.5 mg tabletti SPC 2021-12-02
PL	Resepti/itsehoito	Nasacort 55 mikrog-annos nenäsumute, suspensio SPC 2023-07-15
PL	Itsehoito	Nasment 1 mg-ml nenäsumute, liuos SPC 2021-05-13
PL	Itsehoito	Naso-Ratiopharm 0.5 mg-ml, 1 mg-ml nenäsumute, liuos SPC 2021-02-08
PL	Resepti/itsehoito	Nasofan 50 mikrog-annos nenäsumute, suspensio SPC 2022-09-29
PL	Itsehoito	Nasolin 0.5 mg-ml, 1 mg-ml nenäsumute, liuos SPC 2021-03-26
PL	Itsehoito	Nasolin 0.5 mg-ml, 1 mg-ml nenäsumute, liuos SPC 2021-03-26
PL	Resepti	Nasonex 50 mikrog-annos nenäsumute, suspensio SPC 2021-04-27
		European Medicines Agency's website: Natpar - EMA: EPAR PI Finnish Swedish
PL	Itsehoito	Natr. Chlorid. 9 mg-ml nenätipat, liuos SPC 2021-06-07
PL	Resepti	Natrilix 2.5 mg tabletti, kalvopäällysteinen SPC 2021-12-21
PL	Resepti	Natrilix Retard 1.5 mg depottabletti SPC 2021-11-24
PL	Resepti	Natriumbicarbonate Braun 75 mg-ml infuusioneste SPC 2020-01-09
1  2  3  4  5  6  7  |  Next 30   >